Associations - KRAS mutation

BIOMARKER:

KRAS mutation

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS mutation KRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
KRAS mutation KRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS mutation KRAS mutation	Colorectal Cancer CRC	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine/tipiracil Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS mutation KRAS mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS mutation KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
KRAS mutation KRAS mutation	Colorectal Cancer CRC	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria pembrolizumab + abemaciclib Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2
KRAS mutation KRAS mutation	Colorectal Cancer CRC	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
KRAS mutation KRAS mutation	Colorectal Cancer CRC	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	CYT 387 Sensitive: C2 – Inclusion Criteria CYT 387 Sensitive : C2
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KRAS mutation KRAS mutation	Ovarian Cancer Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES